Fresenius Kabi will invest approximately $250 million over 10 years to expand its Melrose Park, IL, site that manufactures generic, sterile injectable pharmaceuticals. The expansion of the current Melrose Park site into a manufacturing campus is a multistage, multiyear project with ground breaking planned for 2017 and final project completion in 2026.
The plant produces a range of generic injectable medicines. The expansion will create multiple new buildings and will feature fully automated aseptic filling lines using novel isolator technology, expanded lyophilization capabilities, formulation areas, a dedicated warehouse for raw materials and components, and an administration building.
“We are creating a state-of-the-art pharmaceutical manufacturing campus that will be a showcase for our company and the production of injectable generic medicines,” said Steven R. Nowicki, senior vice president of global operations for North America, pharmaceuticals division at Fresenius Kabi. Fresenius Kabi operates more than 70 manufacturing sites across the globe and the Melrose Park location will be one of its largest.
In addition to its Melrose Park locations, Fresenius Kabi has multiple locations in Illinois including Bensenville, Skokie, and Lake Zurich. The company also has manufacturing sites in New York, North Carolina, and Pennsylvania.
